quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:00:00·107d
PRRelease
Zentalis Pharmaceuticals Inc. logo

Zentalis Pharmaceuticals Provides Corporate Update and Highlights Key Milestones and Expected Momentum in the Azenosertib Development Program for 2026

ZNTL· Zentalis Pharmaceuticals Inc.
Health Care
Original source

Companies

  • ZNTL
    Zentalis Pharmaceuticals Inc.
    Health Care

Recent analyst ratings

  • Mar 17UpdateWells Fargo$5.00
  • Aug 12UpdateWedbush$4.00
  • Jun 20UpdateUBS$5.00
  • Jun 18UpdateJefferies$6.00
  • Jun 18UpdateMorgan Stanley$8.00
  • Jun 18UpdateWedbush$4.00

Related

  • PR2d
    Zentalis Pharmaceuticals Announces Abstract Acceptance at ASCO 2026 Featuring Azenosertib in Combination with Paclitaxel for Platinum-Resistant Ovarian Cancer
  • PR6d
    Zentalis Pharmaceuticals To Present Azenosertib Preclinical Data in Triple-Negative Breast Cancer and Real-World Analysis of Unmet Need in Cyclin E1-Positive Ovarian Cancer at AACR 2026
  • SEC6d
    Zentalis Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
  • SEC14d
    Zentalis Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
  • PR14d
    Zentalis Pharmaceuticals Announces 400mg QD 5:2 Azenosertib Monotherapy as the Pivotal Study Dose in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer
  • PR22d
    Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  • SEC28d
    SEC Form 10-K filed by Zentalis Pharmaceuticals Inc.
  • SEC28d
    Zentalis Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022